© Reuters.  Horizon Pharma Q3 revenues up 30%; updates guidance© Reuters. Horizon Pharma Q3 revenues up 30%; updates guidance

  • Horizon Pharma (HZNP -0.1%) Q3 results: Revenues: $271.6M (+30.1%); Operating Loss: ($25.8M) (-21.1%); Net Loss: ($64M); Loss Per Share: ($0.39); Non-GAAP EPS: $0.26 (-62.9%); Quick Assets: $625M (+22.8%); CF Ops: $68.3M (-47.0%).
  • 2017 Guidance: Revenues: $1.030B – 1.050B from $1.010B – 1.045B; Adjusted EBITDA: $350M – 375M from $340M – 375M.
  • Now read: Spero Therapeutics: An Exciting Anti-Microbial IPO

Original article

sponsoredArticle = ‘div-gpt-ad-1466339494851-0’;

LEAVE A REPLY

Please enter your comment!
Please enter your name here